Archived Releases

November 11, 2019
Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Conference Call and Webcast Scheduled for Monday, November 11th at 8:30am Eastern Time REHOVOT, Israel , and BRIDGEWATER, N.J. , Nov. 11, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and
October 23, 2019
Foamix Enters Into Manufacturing and Supply Agreement For AMZEEQ™ and FMX103
Triggers availability of non-dilutive capital under existing credit agreement with Perceptive and OrbiMed REHOVOT, Israel and BRIDGEWATER, N.J. , Oct. 23, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today
October 21, 2019
Foamix Announces Settlement of Litigation with Teva Relating to Finacea Foam
REHOVOT, Israel and BRIDGEWATER, N.J. , Oct. 21, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that, together with LEO Pharma A/S (“LEO Pharma”) it has entered into a settlement and license
Displaying 1 - 10 of 179